• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    2/12/26 4:18:37 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care
    Get the next $GUTS alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    Fractyl Health, Inc.

    (Name of Issuer)


    Common Stock, par value $0.00001 per share

    (Title of Class of Securities)


    35168W103

    (CUSIP Number)


    12/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Mithril LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,160,301.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,160,301.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,160,301.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  All such shares are held of record by Mithril I (as defined in Item 2(a) of the Original Schedule 13G (as defined below)). Mithril GP (as defined in Item 2(a) of the Original Schedule 13G) is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ajay Royan is the authorized person of Mithril GP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP. The investment committee makes all investment decisions with respect to shares held by Mithril I and may be deemed to have shared voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is based on 137,044,440 shares of the Issuer's common stock ("Common Stock") outstanding as of October 31, 2025 as set forth in the Issuer's quarterly report on Form 10-Q for the quarter ended September 30, 2025, filed with the United States Securities and Exchange Commission (the "Commission") on November 12, 2025 (the "Form 10-Q").


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Mithril GP LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    5,160,301.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    5,160,301.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    5,160,301.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    3.8 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  All such shares are held of record by Mithril I. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to these securities. Ajay Royan is the authorized person of Mithril GP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP. The investment committee makes all investment decisions with respect to shares held by Mithril I and may be deemed to have shared voting, investment and dispositive power with respect to these securities. The percentage in Row 11 is on 137,044,440 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Mithril II LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,251,900.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,251,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,251,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  All such shares are held of record by Mithril II (as defined in Item 2(a) of the Original Schedule 13G). Mithril II UGP (as defined in Item 2(a) of the Original Schedule 13G) is the general partner of Mithril II GP (as defined in Item 2(a) of the Original Schedule 13G), which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares. The percentage in Row 11 is on 137,044,440 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Mithril II GP LP
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,251,900.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,251,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,251,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:  All such shares are held of record by Mithril II. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares. The percentage in Row 11 is on 137,044,440 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Mithril II UGP LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,251,900.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,251,900.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,251,900.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.9 %
    12Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:  All such shares are held of record by Mithril II. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment, and dispositive power with respect to the shares held by Mithril II. Ajay Royan is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee established by Mithril II GP. The investment committee makes all investment decisions with respect to the shares held by Mithril II and may be deemed to have shared voting, investment and dispositive power with respect to such shares. The percentage in Row 11 is on 137,044,440 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Ajay Royan
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CANADA (FEDERAL LEVEL)
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    47,901.00
    6Shared Voting Power

    6,412,201.00
    7Sole Dispositive Power

    47,901.00
    8Shared Dispositive Power

    6,412,201.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,460,102.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The shares reported in Rows 5 and 7 consist of (i) 30,000 shares subject to stock options granted to Ajay Royan in his capacity as a director of the Issuer that are exercisable as of the date of filing this Amendment (as defined below) or within 60 days thereafter and (ii) 17,901 shares of Common Stock that Ajay Royan holds directly. The shares reported in Rows 6 and 8 consist of (i) 5,160,301 shares held by Mithril I and (ii) 1,251,900 shares held by Mithril II. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril I. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril II. Ajay Royan is the authorized person of Mithril I GP and is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP and the members of the investment committee established by Mithril II GP. Each of the investment committees makes all investment decisions with respect to the shares held by each of Mithril I and Mithril II, respectively, and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Mithril I and Mithril II. The percentage in Row 11 is on 137,044,440 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    CUSIP No.
    35168W103


    1Names of Reporting Persons

    Peter Thiel
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    6,412,201.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    6,412,201.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    6,412,201.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.7 %
    12Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:  The shares reported in Rows 6 and 8 consist of (i) 5,160,301 shares held by Mithril I and (ii) 1,251,900 shares held by Mithril II. Mithril GP is the general partner of Mithril I and Mithril GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril I. Mithril II UGP is the general partner of Mithril II GP, which is the general partner of Mithril II, and each of Mithril II UGP and Mithril II GP may be deemed to have shared voting, investment and dispositive power with respect to the securities held by Mithril II. Ajay Royan is the authorized person of Mithril I GP and is the sole managing member of Mithril II UGP. Ajay Royan and Peter Thiel are the members of the investment committee of Mithril GP and the members of the investment committee established by Mithril II GP. Each of the investment committees makes all investment decisions with respect to the shares held by each of Mithril I and Mithril II, respectively, and may be deemed to have shared voting, investment and dispositive power with respect to the securities held by each of Mithril I and Mithril II. The percentage in Row 11 is on 137,044,440 shares of Common Stock outstanding as of October 31, 2025, as set forth in the Form 10-Q.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Fractyl Health, Inc.
    (b)Address of issuer's principal executive offices:

    3 Van de Graaff Drive, Suite 200, Burlington, MA 01803
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 1 (this "Amendment") is being filed to amend and restate the Schedule 13G originally filed by the Reporting Persons with the Commission on November 13, 2024 (the "Original Schedule 13G). Only those items that are hereby reported are amended; all other items reported in the Original Schedule 13G remain unchanged. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable. Capitalized terms not defined in this Amendment, have the meanings ascribed to them in the Original Schedule 13G. The Reporting Persons conducted a transaction since the Original Schedule 13G that in the aggregate did not result in a material change of beneficial ownership. This Amendment is being filed to report the decrease of the aggregate percentage of Common Stock owned by the Reporting Persons since the Original Schedule 13G. The material decrease of the aggregate percentage of Common Stock owned by the Reporting Persons resulted from the Issuer's sales of additional shares of its Common Stock.
    (b)Address or principal business office or, if none, residence:

    (c)Citizenship:

    (d)Title of class of securities:

    Common Stock, par value $0.00001 per share
    (e)CUSIP No.:

    35168W103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See Row 9 of the cover page for each Reporting Person and the corresponding comments.*
    (b)Percent of class:

    See Row 11 of the cover page for each Reporting Person and the corresponding comments.*
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See Row 5 of the cover page for each Reporting Person and the corresponding comments.*

     (ii) Shared power to vote or to direct the vote:

    See Row 6 of the cover page for each Reporting Person and the corresponding comments.*

     (iii) Sole power to dispose or to direct the disposition of:

    See Row 7 of the cover page for each Reporting Person and the corresponding comments.*

     (iv) Shared power to dispose or to direct the disposition of:

    See Row 8 of the cover page for each Reporting Person and the corresponding comments.* *Except to the extent of their pecuniary interest therein, each Reporting Person disclaims beneficial ownership of such shares of Common Stock, except for the shares, if any, such Reporting Person holds of record.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Mithril LP
     
    Signature:/s/ Ajay Royan
    Name/Title:Ajay Royan, Authorized Person of Mithril GP LP, the general partner of Mithril LP
    Date:02/12/2026
     
    Mithril GP LP
     
    Signature:/s/ Ajay Royan
    Name/Title:Ajay Royan, Authorized Person
    Date:02/12/2026
     
    Mithril II LP
     
    Signature:/s/ Ajay Royan
    Name/Title:Ajay Royan, Managing Member of Mithril II UGP LLC, the general partner of Mithril II GP LP, the general partner of Mithril II LP
    Date:02/12/2026
     
    Mithril II GP LP
     
    Signature:/s/ Ajay Royan
    Name/Title:Ajay Royan, Managing Member of Mithril II UGP LLC, the general partner of Mithril GP LP
    Date:02/12/2026
     
    Mithril II UGP LLC
     
    Signature:/s/ Ajay Royan
    Name/Title:Ajay Royan, Managing Member
    Date:02/12/2026
     
    Ajay Royan
     
    Signature:/s/ Ajay Royan
    Name/Title:Ajay Royan
    Date:02/12/2026
     
    Peter Thiel
     
    Signature:/s/ Peter Thiel
    Name/Title:Peter Thiel
    Date:02/12/2026
    Get the next $GUTS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GUTS

    DatePrice TargetRatingAnalyst
    1/30/2026$2.00Overweight → Equal-Weight
    Morgan Stanley
    9/15/2025$9.00Buy
    H.C. Wainwright
    8/28/2025$3.60Buy
    Ladenburg Thalmann
    2/28/2024Outperform
    Evercore ISI
    2/27/2024$18.00Overweight
    Morgan Stanley
    2/27/2024$26.00Buy
    BofA Securities
    More analyst ratings

    $GUTS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chief Financial Officer Smith Weber Lara

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:30:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 3 filed by new insider Smith Weber Lara

    3 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    1/14/26 4:15:03 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by President, Chief Product Off. Caplan Jay David

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/17/25 6:00:05 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Lara Smith Weber as Chief Financial Officer to Support Commercial-Stage Preparedness

    BURLINGTON, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes ("T2D"), today announced the appointment of Lara Smith Weber as Chief Financial Officer, effective January 12, 2026. Ms. Smith Weber will oversee finance, accounting, and investor relations; and will serve as a key strategic partner to the Company's executive leadership team and Board of Directors. Ms. Smith Weber brings more than 20 years of financial leadership experience across medtech, biotech, and other growth-oriented industries. She has a str

    1/6/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Enters a Catalyst-Rich 2026 Positioned to Define the Post-GLP-1 Weight Maintenance Therapeutic Category

    Randomized 6-month data from the REMAIN-1 Midpoint Cohort expected in late January 2026 Topline 6-month data from the REMAIN-1 Pivotal Cohort and potential PMA submission expected in H2 2026 Approximately $85.6 million in cash and cash equivalents on hand, supporting execution across planned 2026 milestones Received gross proceeds of $23.0 million from exercises of Tranche A warrants from August 2025 financing, with cash runway into early 2027 BURLINGTON, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company or Fractyl), a metabolic therapeutics company focused on pattern-breaking approaches that treat root causes of obesity and type 2 diabetes (T2D)

    1/5/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    SCHEDULE 13G/A - FRACTYL HEALTH, INC. (0001572616) (Subject)

    2/17/26 4:39:05 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Fractyl Health Inc.

    SCHEDULE 13G/A - FRACTYL HEALTH, INC. (0001572616) (Subject)

    2/12/26 4:18:37 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - FRACTYL HEALTH, INC. (0001572616) (Filer)

    1/29/26 8:00:35 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Fractyl Health downgraded by Morgan Stanley with a new price target

    Morgan Stanley downgraded Fractyl Health from Overweight to Equal-Weight and set a new price target of $2.00

    1/30/26 6:42:49 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    H.C. Wainwright initiated coverage on Fractyl Health with a new price target

    H.C. Wainwright initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $9.00

    9/15/25 8:08:19 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Ladenburg Thalmann initiated coverage on Fractyl Health with a new price target

    Ladenburg Thalmann initiated coverage of Fractyl Health with a rating of Buy and set a new price target of $3.60

    8/28/25 8:09:13 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Rajagopalan Harith bought $19,999 worth of shares (10,416 units at $1.92), increasing direct ownership by 2% to 501,745 units (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    12/8/25 7:05:03 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Royan Ajay bought $22,980 worth of shares (17,901 units at $1.28) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 7:57:09 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Director Barnes Kelly Ann bought $40,210 worth of shares (31,000 units at $1.30) (SEC Form 4)

    4 - FRACTYL HEALTH, INC. (0001572616) (Issuer)

    3/18/25 4:50:44 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/14/24 4:30:50 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - FRACTYL HEALTH, INC. (0001572616) (Subject)

    11/13/24 5:17:27 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Fractyl Health Inc.

    SC 13G - Fractyl Health, Inc. (0001572616) (Subject)

    2/16/24 9:43:25 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Financials

    Live finance-specific insights

    View All

    Fractyl Health Announces Compelling 6-Month Randomized REMAIN-1 Midpoint Data Showing Durable Weight Maintenance with Revita® After GLP-1 Discontinuation

    Revita-treated patients experienced sustained weight maintenance, improved cardiometabolic profile, and reduced food cravings at 6 months compared with sham, with continued excellent safety and tolerability Patients with above median GLP-1-associated weight loss experienced ~ 70% less post-GLP-1 weight regain with Revita vs sham at 6 months Results support pivotal study design and further substantiate Revita's potential to be the first durable procedural therapy for post-GLP-1 weight maintenance; topline 6-month pivotal data and potential FDA filing expected in H2 2026 Based on ongoing interactions and favorable safety data to date, the Company has requested FDA feedback on reclassifying

    1/29/26 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Third Quarter 2025 Financial Results and Provide Business Updates on November 12, 2025

    BURLINGTON, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the Company), a metabolic therapeutics company focused on pattern-breaking approaches to treat the root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the third quarter 2025 and provide business updates on Wednesday, November 12, 2025, at 4:30 p.m. ET. A live webcast of the conference call and presentation can be accessed in the "Events" section of Fractyl Health's website at http://ir.fractyl.com. The webcast will be archived and available for replay following the live event. About Fractyl Health Fractyl Health is a metabolic therapeutics company f

    11/5/25 7:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health to Report Second Quarter 2025 Financial Results and Provide Business Updates on August 12, 2025, and Will Participate in an Upcoming Investor Conference

    BURLINGTON, Mass., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company" or "Fractyl"), a metabolic therapeutics company focused on pattern breaking approaches that treat root causes of obesity and type 2 diabetes (T2D), today announced it will report financial results for the second quarter 2025 and provide business updates on Tuesday, August 12, 2025, at 4:30 p.m. ET. The Company also announced that Harith Rajagopalan, M.D., Ph.D., Co-Founder and Chief Executive Officer of Fractyl Health, will present at the Canaccord Genuity 45th Annual Growth Conference on Wednesday, August 13, 2025, at 11:30 a.m. ET. A live webcast of the conference call and presentatio

    8/6/25 4:05:00 PM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    $GUTS
    Leadership Updates

    Live Leadership Updates

    View All

    Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes

    BURLINGTON, Mass., April 02, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) (the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of obesity and type 2 diabetes (T2D), today announced the appointment of Adrian Kimber as Chief Commercial Officer. Mr. Kimber joins Fractyl with over two decades of experience in the biotechnology and medical devices sectors. Throughout his career, he has showcased a commendable history of introducing groundbreaking therapies to worldwide markets. Renowned for his adeptness in formulating go-to-market strategies, assembling and leading commercial teams, and implementing operational excellence, he

    4/2/24 8:00:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care

    Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials

    LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Fractyl Health, Inc. (NASDAQ:GUTS) ("Fractyl Health" or the "Company"), a metabolic therapeutics company focused on pioneering new approaches for the treatment of Type 2 Diabetes (T2D) and obesity, today announced the appointment of Samuel Conaway to its Board of Directors. Mr. Conaway's extensive background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany. "Sam Conaway's

    2/20/24 8:38:00 AM ET
    $GUTS
    Medical/Dental Instruments
    Health Care